Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
Earnings Data
Report Date
Feb 05, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.14Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive advancements in clinical trials and strong financial positioning, contrasted by the setback of a negative CHMP opinion in Europe for blarcamesine and a decrease in R&D spending. Despite the challenges, the company remains optimistic about its scientific data and future regulatory discussions.Company Guidance
Positive Clinical Data for Blarcamesine
The Phase 2b/3 trial demonstrated significant cognitive benefits in Alzheimer's patients, with patients showing less cognitive decline compared to a control group over 48 and 96 weeks. The defined precision medicine population exhibited a significant clinical improvement.
Successful Phase 2 Trial for ANAVEX 3-71
ANAVEX 3-71 showed positive results in a Phase 2 trial for schizophrenia, achieving its primary endpoint of safety and tolerability, with no serious adverse events reported.
Strong Financial Position
Anavex reported a cash position of $120 million as of September 30, 2025, with a cash runway of more than three years, and no debt.
Scientific Publications and Presentations
Anavex announced several scientific publications, including studies on blarcamesine's effects on memory impairment and brain oxidative injury, and plans to present additional data at upcoming conferences.
AVXL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AVXL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 25, 2025 | $3.08 | $3.46 | +12.34% |
Aug 12, 2025 | $11.35 | $10.78 | -5.02% |
May 13, 2025 | $8.55 | $8.12 | -5.03% |
Feb 12, 2025 | $8.29 | $8.70 | +4.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Anavex Life Sciences (AVXL) report earnings?
Anavex Life Sciences (AVXL) is schdueled to report earning on Feb 05, 2026, TBA (Confirmed).
What is Anavex Life Sciences (AVXL) earnings time?
Anavex Life Sciences (AVXL) earnings time is at Feb 05, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AVXL EPS forecast?
AVXL EPS forecast for the fiscal quarter 2026 (Q1) is -0.12.
